Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsTom Trimarchi is recorded as CFO at BridgeBio Pharma, Inc. (BBIO). Tom Trimarchi has spoken on 6 earnings calls and 2 other investor events across 1 company, most recently for BridgeBio Pharma, Inc. on October 29, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“I'll now walk through our financial results from the third quarter of 2026. Our commentary will focus on GAAP financials unless otherwise noted. Total revenues for the third quarter of 2026 were $353.2 million compared to $120.7 million for the same period in 2025.”
“It's great to be back in New York, sun shining. The next one in the finals.”
“I can start and maybe pass over to my fill in some blanks. So BridgeBio is a biotech company that was founded just over 10 years ago now. And we were created to do two things.”
“Given the already 500 or so genetically confirmed patients in the United States to date, the highly engaged patient community, and physician education being conducted by the team.”
Biotechnology · Healthcare
CFO
